TY - JOUR
T1 - Safety and efficacy of plasma-activated water on prolonged viral shedding of COVID-19 patients
T2 - A randomized controlled trial
AU - Guo, Xiaoya
AU - Lv, Xing
AU - Wu, Yunfu
AU - Wang, Mingming
AU - Wu, Shuo
AU - Guo, Li
AU - Wang, Zifeng
AU - Shi, Zhihong
AU - Huang, Rui
AU - Zhang, Hua
AU - Niu, Xiaona
AU - Rong, Mingzhe
AU - Song, Liqiang
AU - Liu, Dingxin
N1 - Publisher Copyright:
© 2023 Wiley-VCH GmbH.
PY - 2024/4
Y1 - 2024/4
N2 - Shortening the duration of the viral shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to controlling viral transmission, alleviating the burden on the healthcare system, and ultimately mitigating the impact of the pandemic. This randomized, single-blind, placebo-controlled clinical trial aimed to investigate the safety and efficacy of gargling with plasma-activated water (PAW) on prolonged viral shedding in patients infected with SARS-CoV-2 Delta and Omicron variants. Sixty-two subjects, aged 18–80 years and infected with SARS-CoV-2, were recruited at two coronavirus disease 2019 (COVID-19)-designated hospitals in Shaanxi from January to March 2022. Primary outcomes included cumulative conversion rates, incidence of adverse reactions, and biosafety parameters. Results suggested that PAW gargling treatment might contribute to reducing the duration of SARS-CoV-2 Delta and Omicron variant infections and alleviating symptoms.
AB - Shortening the duration of the viral shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical to controlling viral transmission, alleviating the burden on the healthcare system, and ultimately mitigating the impact of the pandemic. This randomized, single-blind, placebo-controlled clinical trial aimed to investigate the safety and efficacy of gargling with plasma-activated water (PAW) on prolonged viral shedding in patients infected with SARS-CoV-2 Delta and Omicron variants. Sixty-two subjects, aged 18–80 years and infected with SARS-CoV-2, were recruited at two coronavirus disease 2019 (COVID-19)-designated hospitals in Shaanxi from January to March 2022. Primary outcomes included cumulative conversion rates, incidence of adverse reactions, and biosafety parameters. Results suggested that PAW gargling treatment might contribute to reducing the duration of SARS-CoV-2 Delta and Omicron variant infections and alleviating symptoms.
KW - COVID-19
KW - Delta variant
KW - Omicron variant
KW - plasma-activated water
KW - randomized controlled trial
UR - https://www.scopus.com/pages/publications/85180201605
U2 - 10.1002/ppap.202300195
DO - 10.1002/ppap.202300195
M3 - 文章
AN - SCOPUS:85180201605
SN - 1612-8850
VL - 21
JO - Plasma Processes and Polymers
JF - Plasma Processes and Polymers
IS - 4
M1 - 2300195
ER -